drugset
drugset / Trial / NCT04456361

Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19

NCT04456361 ↗

Phase 0 Unknown 9 enrolled Instituto de Medicina Regenerativa
NaSingle-groupOpen-labelTreatment

Summary

This is a pilot phase, open label, non-randomized study for the treatment of ARDS in patients infected with COVID-19. Subjects will be enrolled and treated with one dose of mesenchymal stem cells and follow-up will occur 90 days post-treatment.

Timeline

Start
2020-04-16
Primary completion
2025-02-15
Completion
2025-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 1e+08 cells Intravenous

Indications

COVID-19 acute respiratory distress syndrome